CymaBay Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
CymaBay Therapeutics has a total shareholder equity of $292.3M and total debt of $109.2M, which brings its debt-to-equity ratio to 37.4%. Its total assets and total liabilities are $434.7M and $142.4M respectively.
Key information
37.4%
Debt to equity ratio
US$109.17m
Debt
Interest coverage ratio | n/a |
Cash | US$394.26m |
Equity | US$292.26m |
Total liabilities | US$142.43m |
Total assets | US$434.69m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: C0I's short term assets ($403.8M) exceed its short term liabilities ($36.8M).
Long Term Liabilities: C0I's short term assets ($403.8M) exceed its long term liabilities ($105.6M).
Debt to Equity History and Analysis
Debt Level: C0I has more cash than its total debt.
Reducing Debt: C0I's debt to equity ratio has increased from 0% to 37.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: C0I has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if C0I has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.